Market Place
Sourcing Support
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
30 Oct 2024 //
PR NEWSWIRE
Hansa Biopharma Reports Q3 And Interim January-September 2024 Results
16 Oct 2024 //
PR NEWSWIRE
Hansa Biopharma Reports Positive NICE-01 Trial Results
08 Oct 2024 //
PHARMABIZ
Hansa Biopharma Joins H.C. Wainwright Global Investment Conference
05 Sep 2024 //
PR NEWSWIRE
Hansa Chief Commercial Officer Departs the Company
26 Aug 2024 //
CONTRACT PHARMA
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
23 Aug 2024 //
PR NEWSWIRE
Hansa Biopharma Reports Q2 2024 Financial Results And Business Update
18 Jul 2024 //
PR NEWSWIRE
Hansa Biopharma to host Q2 2024 interim results conference call
03 Jul 2024 //
PR NEWSWIRE
Hansa Biopharma: increase in number of shares and votes
28 Jun 2024 //
PR NEWSWIRE
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
31 May 2024 //
PR NEWSWIRE
Hansa Biopharma To Present Data At Transplant Congress 2024
21 May 2024 //
PR NEWSWIRE
Hansa Biopharma: increase in number of shares and votes
03 May 2024 //
PR NEWSWIRE
Hansa Biopharma interim report January-March 2024
18 Apr 2024 //
PR NEWSWIRE
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
02 Apr 2024 //
PR NEWSWIRE
Hansa Biopharma Year-end report January-December 2023
01 Feb 2024 //
PR NEWSWIRE
Hansa Biopharma provides update on business
07 Jan 2024 //
PR NEWSWIRE
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 in patients with AMR
14 Dec 2023 //
PR NEWSWIRE
Hansa Biopharma Nomination Committee formed
13 Dec 2023 //
PR NEWSWIRE
Imlifidase demonstrated positive safety efficacy outcomes phase 2 trial in GBS
06 Dec 2023 //
PR NEWSWIRE
Hansa Biopharma plans restructuring
05 Dec 2023 //
PR NEWSWIRE
Hansa Biopharma Interim Report January-September 2023
26 Oct 2023 //
PR NEWSWIRE
Hansa Biopharma Names Hitto Kaufmann Chief Scientific Officer
01 Sep 2023 //
CONTRACT PHARMA
Hansa Biopharma half year report 2023
20 Jul 2023 //
PR NEWSWIRE
First patient treated with imlifidase in an investigator-initiated Phase 2 study
19 Jul 2023 //
PR NEWSWIRE
Hansa to host conference call to provide half year results for January-June 2023
06 Jul 2023 //
PR NEWSWIRE
Hansa recognizes write-up of SEK 1.430B in intangible assets related to Idefirix
04 Jul 2023 //
PR NEWSWIRE
Hansa Biopharma announces positive reimbursement decision for Idefirix
01 Jun 2023 //
PR NEWSWIRE
Hansa announces first patient dosed imlifidase in a global pivotal ph3 trial
30 May 2023 //
PR NEWSWIRE
Hansa starts dosing in Phase III trial in anti-GBM disease
30 May 2023 //
CLINICAL TRIALS ARENA
Hansa Biopharma publishes Annual Report 2022
30 Mar 2023 //
PR NEWSWIRE
Hansa Biopharma Year-end report January-December 2022
02 Feb 2023 //
PR NEWSWIRE
Hansa Biopharma announces positive reimbursement decision for Idefirix
03 Jan 2023 //
PR NEWSWIRE
Hansa Biopharma: Increase of the number of shares and votes
30 Dec 2022 //
PR NEWSWIRE
Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix
08 Dec 2022 //
PRNEWSWIRE
Hansa Biopharma & Sarepta plan to initiate a clinical study with imlifidase
02 Nov 2022 //
PRNEWSWIRE
SMC recommends use of Hansa Biopharma`s Idefirix as desensitization treatment
12 Sep 2022 //
PRNEWSWIRE
Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
09 Sep 2022 //
PRNEWSWIRE
Hansa Biopharma and Medison Pharma announce positive reimbursement decision
22 Aug 2022 //
PRNEWSWIRE
Hansa Biopharma half year report 2022
19 Jul 2022 //
PRNEWSWIRE
NICE recommends use of Hansa Biopharma`s Idefirix as desensitization treatment
16 Jun 2022 //
PRNEWSWIRE
Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors
30 May 2022 //
PRNEWSWIRE
Hansa Biopharma: Notice to Annual General Meeting
30 May 2022 //
PRNEWSWIRE
Hansa Biopharma completes enrollment in imlifidase phase 2 study
23 May 2022 //
PRNEWSWIRE
Alzheimer’s: Delhi pharma firm gets B’luru scientists’ drug IP
12 May 2022 //
ET HEALTH
Hansa Biopharma interim report January - March 2022
20 Apr 2022 //
PRNEWSWIRE
Hansa Biopharma announces positive early access decision by French HAS
26 Feb 2022 //
BIOSPACE
Hansa Biopharma provides business update including certain key financials
09 Jan 2022 //
PRNEWSWIRE
Hansa Biopharma enrolls first patient in U.S. randomized, controlled
29 Dec 2021 //
PRNEWSWIRE
Hansa & Medison partner for desensitization treatment for kidney transplant
07 Dec 2021 //
PRNEWSWIRE
Hansa Biopharma to start Phase III anti-GBM disease therapy trial
15 Nov 2021 //
CLINICALTRIALSARENA
Hansa Biopharma to initiate Phase 3 study of imlifidase (anti-GBM)
13 Nov 2021 //
PRESSRELEASE
Hansa confidentially submits draft registration statement on Form F-1 to SEC
08 Nov 2021 //
PRNEWSWIRE
Hansa Biopharma to host conference call to provide interim results
07 Oct 2021 //
PRNEWSWIRE
Hansa Biopharma achieves Great Place to Work certification
25 Aug 2021 //
PRNEWSWIRE
Hansa Biopharma to host conference call to provide interim results
01 Jul 2021 //
PR NEWSWIRE
Hansa Biopharma enters preclinical research collaboration with argenx
29 Mar 2021 //
PRNEWSWIRE
Hansa Biopharm announces positive results from phase 2 trial of imlifidase
25 Sep 2020 //
PHARMABIZ
Hansa Biopharm announces positive data from phII trial with imlifidase
24 Sep 2020 //
PRNEWSWIRE
Hansa Biopharma`s Idefirix (Imlifidase) Receives Approval In Europe
13 Sep 2020 //
EMA
Hansa Biopharma provides updated guidance on its clinical programs
01 Sep 2020 //
PRNEWSWIRE
